As pioneers in neuroscience, Biogen has an innovative therapeutic pipeline that aims to reverse disability, repair damage, and address other remaining unmet needs in MS, with the goal of …

View Biogen products for Multiple Sclerosis, Spinal Muscular Atrophy & Biosimilars

Apr 8, 2025 · Our medicines aim to improve the well-being of people around the world. Below is a list of our company's therapies. The below information is intended for U.S. residents only. For …

Biogen Scientific Leadership in MS is demonstrated through the current assets under clinical development geared toward addressing significant unmet needs, as well as the life cycle

VUMERITY is a prescription medicine used to treat people with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active …

Biogen offers five approved treatments for relapsing MS. Learn more about each option to help you make an informed decision. Biogen Support Services can provide help with financial, …

Sep 19, 2024 · For more than 25 years Biogen has been a leader in the research and development of new medications for multiple sclerosis (MS). Our understanding of the disease …

May 27, 2016 · CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.-- (BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) approved ZINBRYTA TM (daclizumab), a new once …

Biogen provides a range of resources to support the educational development of healthcare professionals involved in MS. Find the latest information about Spinal Muscular Atrophy (SMA) …

Aug 15, 2014 · CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved PLEGRIDY TM …